1. In Vivo
  2. >>ESG

The E in ESG: Data Reporting To Meet Healthcare’s Sustainability Challenge

EU Consultation On CSRD Standards And New Compliance Documents From IFRS

 
• By Ashley Yeo

High quality data reporting will be crucial if the healthcare and life sciences sectors are to achieve net zero compliance of carbon emissions. This 12th instalment of In Vivo’s rolling E in ESG series reports on the growing body of disclosure and reporting laws and platforms.

Shutterstock

“When you know where you are, you know where you need to get to,” said Laura Kelly, director of sustainability practice, PricewaterhouseCoopers, as she addressed a Westminster Health Forum meeting on compliance with net zero demands.

The ESG reporting landscape is complex, but a sound understanding of requirements will be vital to the success of companies – and suppliers – on their journey to net zero, Kelly explained at the 24 April meeting

Key Takeaways

EU assumes early role of thought leader on sustainability compliance and the reporting of compliance

Medtech leader Medtronic's 15-year record of sustainability compliance and reporting

Global approach to

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from ESG

RESILIENCE Initiative Navigates The World Of Making Medicines Through VR Technology

 
• By Anabel Costa-Ferreira

The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.

Cracking Through ‘The Bamboo Ceiling’: East Asians Reach For Pharma Leadership

 
• By Brian Yang

Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.

Infographic: Analyzing The Gap In Women’s Health Care

 
• By Anabel Costa-Ferreira

Looking at a recent McKinsey report alongside our Evaluate data, the below infographic provides insight into the investment scene of pharma and raises questions as to how the industry is seemingly yet to seize the opportunity in women's health.

Growing Calls For Labelling Changes With Obesity Patients In Mind

 
• By Ed Silverman

Despite significant investments in weight loss treatments, pharmaceutical companies face criticism for neglecting to study their drugs in obese patients, possibly leading to incomplete labeling and patient risks, prompting calls for the FDA to enforce more inclusive clinical trials and updated drug information.

More from In Vivo

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.

Rising Leaders 2025: Flagship’s Jacob Rubens On Building The Next Generation Of Biotech

 
• By David Wild

Rising Leader Jacob Rubens, who has co-founded and led several Flagship companies and is now origination partner, believes aspiring leaders should follow their bliss.